Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody
- 13 September 2004
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 100 (1), 135-144
- https://doi.org/10.1016/j.jconrel.2004.08.007
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*Cancer Investigation, 2003
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdvances in Enzyme Regulation, 2001
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of ChemotherapyCancer Investigation, 2001
- Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer, 2000
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- Which polymers can make nanoparticulate drug carriers long-circulating?Advanced Drug Delivery Reviews, 1995
- Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitroBiochimica et Biophysica Acta (BBA) - Biomembranes, 1995
- Molecular mechanism of the lipid vesicle longevity in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 1993
- Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesiclesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomesFEBS Letters, 1990